Cite

    Joshi, G. et al. (2020). A prospective open-label trial of long-acting liquid methylphenidate for the treatment of attention deficit/hyperactivity disorder in intellectually capable adults with autism spectrum disorder. World journal of biological psychiatry. pp. 274-290. [Online].